TY - JOUR
T1 - Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen
AU - Diamos, Andrew G.
AU - Larios, Dalia
AU - Brown, Lauren
AU - Kilbourne, Jacquelyn
AU - Kim, Hyun Soon
AU - Saxena, Divyasha
AU - Palmer, Kenneth E.
AU - Mason, Hugh S.
N1 - Funding Information:
This work was supported by NIH-NIAID grant U19-AI062150-01 , and funds provided by the Center for Immunotherapy, Vaccines, and Virotherapy of the Biodesign Insitute at ASU . We thank Zhong Huang, Khanrat Piensook, Mike Lopker, and Andrew Osahor at ASU for preliminary studies that supported and informed this work.
Funding Information:
This work was supported by NIH-NIAID grant U19-AI062150-01, and funds provided by the Center for Immunotherapy, Vaccines, and Virotherapy of the Biodesign Insitute at ASU. We thank Zhong Huang, Khanrat Piensook, Mike Lopker, and Andrew Osahor at ASU for preliminary studies that supported and informed this work.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2019/1/3
Y1 - 2019/1/3
N2 - Diverse HPV subtypes are responsible for considerable disease burden worldwide, necessitating safe, cheap, and effective vaccines. The HPV minor capsid protein L2 is a promising candidate to create broadly protective HPV vaccines, though it is poorly immunogenic by itself. To create highly immunogenic and safe vaccine candidates targeting L2, we employed a plant-based recombinant protein expression system to produce two different vaccine candidates: L2 displayed on the surface of hepatitis B core (HBc) virus-like particles (VLPs) or L2 genetically fused to an immunoglobulin capable of forming recombinant immune complexes (RIC). Both vaccine candidates were potently immunogenic in mice, but were especially so when delivered together, generating very consistent and high antibody titers directed against HPV L2 (>1,000,000) that correlated with virus neutralization. These data indicate a novel immune response synergy upon co-delivery of VLP and RIC platforms, a strategy that can be adapted generally for many different antigens.
AB - Diverse HPV subtypes are responsible for considerable disease burden worldwide, necessitating safe, cheap, and effective vaccines. The HPV minor capsid protein L2 is a promising candidate to create broadly protective HPV vaccines, though it is poorly immunogenic by itself. To create highly immunogenic and safe vaccine candidates targeting L2, we employed a plant-based recombinant protein expression system to produce two different vaccine candidates: L2 displayed on the surface of hepatitis B core (HBc) virus-like particles (VLPs) or L2 genetically fused to an immunoglobulin capable of forming recombinant immune complexes (RIC). Both vaccine candidates were potently immunogenic in mice, but were especially so when delivered together, generating very consistent and high antibody titers directed against HPV L2 (>1,000,000) that correlated with virus neutralization. These data indicate a novel immune response synergy upon co-delivery of VLP and RIC platforms, a strategy that can be adapted generally for many different antigens.
KW - Human papillomavirus
KW - Minor capsid protein
KW - Recombinant immune complex
KW - Vaccine
KW - Virus-like particle
UR - http://www.scopus.com/inward/record.url?scp=85056746462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056746462&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2018.11.021
DO - 10.1016/j.vaccine.2018.11.021
M3 - Article
C2 - 30459071
AN - SCOPUS:85056746462
SN - 0264-410X
VL - 37
SP - 137
EP - 144
JO - Vaccine
JF - Vaccine
IS - 1
ER -